Pharnext houdt bedrijfspresentatie op de H.C. Wainwright Annual Global Life Sciences Conference
PARIJS – (BUSINESS WIRE) – Regulatory News:
Pharnext SA (Parijs: ALPHA) (FR0011191287 – ALPHA), een biofarmaceutisch bedrijf dat baanbrekend werk verricht voor een nieuwe aanpak van de ontwikkeling van innovatieve geneesmiddelen op basis van de combinatie en herpositionering van bekende geneesmiddelen, heeft vandaag aangekondigd dat het bedrijfsmanagement een bedrijfsoverzicht zal presenteren bij het H.C. Wainwright Annual Global Life Sciences Conference.
De presentatie zal als volgt plaatsvinden:
- Datum: dinsdag 10 april 2018
- Tijd: 14.10 uur CEST
- Locatie: Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco
De eerste PLEODRUG ™, PXT3003 van Pharnext, bevindt zich momenteel in een internationale derde fase-studie voor de behandeling van de zeldzame ziekte van Charcot-Marie-Tooth type 1A. De resultaten van deze proef worden verwacht voor het einde van 2018.
Als je tijdens dit evenement interesse hebt om het managementteam van Pharnext te ontmoeten of als je meer informatie wilt over de deelname van Pharnext, stuur dan een e-mail naar investors@pharnext.com
Pharnext to Present at the H.C. Wainwright Annual Global Life Sciences Conference
PARIS–(BUSINESS WIRE)– Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference.
The presentation will take place as follows:
- Date: Tuesday, April 10th, 2018
- Time: 2:10 pm CEST
- Venue: Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco
Pharnext’s first-in-class PLEODRUG™, PXT3003, is currently in an international Phase 3 trial for the treatment of the rare disease Charcot-Marie-Tooth disease type 1A. The results of this trial are expected before the end of 2018.
If you are interested in meeting the Pharnext management team during this event or if you need more information about Pharnext’s participation, please send an email to investors@pharnext.com
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180329005796/en/
Contacts
Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
contact@pharnext.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol / Aurore Gangloff
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (U.S.)
RooneyPartners
Marion Janic, +1 212 223 4017
mjanic@rooneyco.com
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Check out our twitter: @NewsNovumpr